Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke

Clin Dev Immunol. 2012:2012:981519. doi: 10.1155/2012/981519. Epub 2012 Mar 25.

Abstract

Objectives: To evaluate the frequency of seizures in primary antiphospholipid syndrome (PAPS) and their possible clinical and laboratory associations.

Methods: Eighty-eight PAPS patients (Sydney's criteria) were analyzed by a standard interview, physical examination and review of medical charts. Risk factors for seizures, clinical manifestations, associated comorbidities, and antiphospholipid antibodies were evaluated.

Results: Nine (10.2%) patients with seizures were identified, 77.8% had convulsions onset after PAPS diagnosis. Mean age, gender, and race were comparable in groups with or without seizures. Interestingly, a higher frequency of current smoking (44.4 versus 10.1%, P = 0.019) was observed in the first group. Stroke, Sneddon's syndrome, and livedo reticularis were more frequent in PAPS patients with seizures than those without seizures, although not statistically significant (P > 0.05). Comparison between patients with seizures onset after PAPS diagnosis (n = 7) and those without convulsions (n = 79) demonstrated a higher frequency of current smoking (42.9 versus 10%, P = 0.042) and stroke in the first group (71.4 versus 30.4%, P = 0.041). Regression analysis confirmed that smoking (P = 0.030) and stroke (P = 0.042) were independently associated to seizures.

Conclusion: About 10.2% of PAPS patients had convulsions, predominantly after PAPS diagnosis, and seizures were associated to current smoking and stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Antibodies, Antiphospholipid / blood
  • Antiphospholipid Syndrome / blood
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Regression Analysis
  • Risk Factors
  • Seizures / blood
  • Seizures / physiopathology*
  • Smoking / adverse effects*
  • Sneddon Syndrome / blood
  • Sneddon Syndrome / etiology
  • Sneddon Syndrome / physiopathology
  • Stroke / blood
  • Stroke / etiology*
  • Stroke / physiopathology

Substances

  • Antibodies, Antiphospholipid